Gilead Sciences, Inc. (GILD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

SA Transcripts 162.15K Followers Follow Gilead Sciences, Inc. ( GILD ) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 11:00 AM EDT Company Participants Dietmar Berger - Chief Medical Officer Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Wells Fargo Securities, LLC, Research Division Awesome. Thank you very much for joining us today. My name is Mohit Bansal. I am one of the biotech and pharma analysts here at Wells Fargo, and I am joined by Dr. Dietmar Berger, Gilead's Chief Medical Officer. Thank you very much, Dietmar, for joining us today for the first time. Dietmar Berger Chief Medical Officer Thanks for having me. Yes, of course. Mohit Bansal Wells Fargo Securities, LLC, Research Division Awesome. Gilead has been a regular. This is fifth year in a row at Wells Fargo Conference, first time for Dietmar. We are excited to have some R&D discussions here. Dietmar Berger Chief Medical Officer Yes. Question-and-Answer Session Mohit Bansal Wells Fargo Securities, LLC, Research Division So Dietmar, let's just talk a little bit about the pipeline focus right now. It does seem like you have a mix of, obviously, building on HIV, where you have a leadership, and then oncology, some datasets coming in, immunology as well. Talk a little bit about when you look at the internal portfolio and some of the assets you acquired earlier this year, where is the focus internally is, and then what do you see the most exciting stuff out there? Dietmar Berger Chief Medical Officer Yes. No, thanks for that question. The current management team at Gilead, they joined 7 years ago. There was a clear realization that we want to diversify. That's been our strategy for some time, and we've clearly highlighted, yes, we have a clear stronghold in virology, and there's diversification in virology as well. That's important to us. Then there's really this expansion into oncology